Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant mFOLFOXIRI for EMVI+ Rectal Cancer
NCT04170530Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2019
- Primary completion
- Nov 2020
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, folinic acid, oxaliplatin, irinotecan in rectal cancer, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Status: unknown.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04170530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04170530.